All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Azithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2021
Details:
The independent Trial Steering Committee concluded that both azithromycin and doxycycline are generally ineffective against early-stage COVID-19 in patients over 50 who are treated with either antibiotic at home.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Interferon Beta-1A
Therapeutic Area: Infections and Infectious Diseases Product Name: SNG001
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2021
Details:
First patient has been dosed in the UK as part of its global Phase III trial (SG018) evaluating Synairgen’s inhaled formulation of interferon beta-1a (SNG001), for the treatment of hospitalised COVID-19 patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2020
Details:
COV001 is a blinded, multi-centre, randomised, controlled Phase I/II trial assessing safety, immunogenicity and efficacy of AZD1222 in 1,077 healthy adults in five trial centres in the UK.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2020
Details:
Results of an interim analysis of the Phase III programme of AZD1222, demonstrated that the vaccine is safe and effective at preventing symptomatic COVID-19 and that it protects against severe disease and hospitalisation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: AstraZeneca PLC
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
Researchers show overall vaccine (ChAdOx1 nCoV-19) efficacy of 70.4% from a pooled analysis of two-dose regimen. Efficacy results are based on data taken from 11,636 volunteers across the U. K and Brazil.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RSVPreF3
Therapeutic Area: Infections and Infectious Diseases Product Name: GSK3888550A
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
Patient dosing has begun in a phase 3 clinical programme investigating the safety and efficacy of its Respiratory Syncytial Virus candidate vaccine for maternal immunisation (GSK3888550A), after presentation of positive phase 1/2 safety, reactogenicity and immunogenicity data.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ChAdOx1 nCoV-19,Paracetamol
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: University of Oxford
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
One dosing regimen showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen showed 62% efficacy when given as two full doses at least one month apart.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cabotegravir,Tenofovir Disoproxil Fumarate,Emtricitabine
Therapeutic Area: Infections and Infectious Diseases Product Name: Vocabria
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2020
Details:
The breakthrough therapy designation is based on efficacy and safety results from HPTN 083, a phase IIb/III clinical trial that compared long-acting, injectable cabotegravir to daily oral emtricitabine/tenofovir disoproxil fumarate 200 mg and 300 mg for HIV prevention.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cabotegravir,Tenofovir Disoproxil Fumarate,Emtricitabine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
